VIALE study criteria for those ineligible for 7+3
Age: > 75
ECOG 2 or higher
CHF EF 50% or less, chronic stable angina, COPD FEV1< 65% or DLCO< 65%
Median OS 15 months versus 9 months with addition of Ven to AZA
NPM1 mutated AML without signaling mutations (TP53, FLT3, NRAS , KRAS) median OS 39 months
Genetic signature with high benefit, intermediate benefit and low benefit to the above rx:
1. Low benefit: TP 53 mutated, median OS 5.5 months ( there was no benefit to adding ven to this group compared to placebo)
2. Intermediate: FLT3/KRAS/or NRAS mutated but with NO TP 53 mutation ( or wildtype TP 53): median OS 12 months
3. High benefit: none of the above mutations. Cr+Cri 77%. Median OF 26 months
No comments:
Post a Comment